Drug Trial Radar · NCT07231861
Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Dec 12, 2025
Primary completion
Dec 21, 2025
Study completion Jan 7, 2026
Sponsor
- Lead sponsor
- AJU Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.
Conditions
- Bronchial Asthma
- Perennial Allergic Rhinitis
Interventions
AJU-R713Drug
Oral formulation
R713RDrug
Oral formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of PranlukastTime frame: 0 hour ~ 24 hour after drug administration
- AUCt of PranlukastTime frame: 0 hour ~ 24 hour after drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H Plus Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.